Cancer

CHEO researchers look at cancer in the lab and at the bed side. For instance, some of our scientists consider biology by analyzing tumor biopsies, and others determine which virus therapies can wipeout cancer cells. While our pediatric oncologists address treatment options by looking at what timing is optimal for administering chemotherapy; whether or not acupuncture helps to alleviate nausea; if natural supplements can help to stimulate appetite – the bottom line is to fight cancer for kids!

CHEO is a member of the Children’s Oncology Group (COG) which aims to understand the causes of cancer and find more effective treatments for children. As part of this international research network, our clinical pediatric cancer researchers have access to funding, treatments, research support and services specifically aimed at better outcomes for kids.

Many CHEO oncologists are pursuing research interests, independent of the COG network. Our diverse team of clinical investigators are collaborating on more than 30 multi-centre studies ranging in topics from evaluating the cardiac late effects in childhood cancer survivors; to looking at central line dysfunction in children with cancer; to applying biomarkers to long term effects of childhood/adolescent cancer treatment; and even equipping patients with iPhones to record their pain scale.

Furthermore, half of our esteemed senior scientists are looking at cancer from an altogether different standpoint – in the laboratory. We are leading world class experiments using protein synthesis, oncolytic virus therapies, and anti-IAP drugs with the goal of getting into clinical trials as soon as possible.

Oncology research is very broad, active portfolio at CHEO and we invite you to contact us to learn more.

Related News

Research Projects

  1. The identification of dual protective agents against cisplatin-induced oto-and nephrotoxicity using the zebrafish model

    28/07/2020

    Dose-limiting toxicities for cisplatin administration, including ototoxicity and nephrotoxicity, impact the clinical utility of this effective chemotherapy agent and lead to lifelong complications, particularly in pediatric cancer survivors. Using a two-pronged drug screen employing the zebrafish lateral line as an in vivo readout for ototoxicity and kidney cell-based nephrotoxicity assay, we screened 1280 compounds and identified 22 that were both oto- and nephroprotective.

  2. Genome Editing in Zebrafish Using High-Fidelity Cas9 Nucleases: Choosing the Right Nuclease for the Task

    01/02/2020

    In summary, the developed new high-fidelity Cas9 vectors will enable researchers to perform much more accurate genome editing.

  3. The Zebrafish Xenograft Platform-A Novel Tool for Modeling KSHV-Associated Diseases

    20/12/2019

    We found that PEL cell proliferation in xenografts was dependent on the host hypoxia-dependent translation initiation factor, eukaryotic initiation factor 4E2 (eIF4E2). This demonstrates that the zebrafish yolk sac is a functionally hypoxic environment, and xenografted cells must switch to dedicated hypoxic gene expression machinery to survive and proliferate. The establishment of the PEL xenograft model enables future studies that exploit the innate advantages of the zebrafish as a model for genetic and pharmacologic screens.

  4. Induction of an Alternative mRNA 5′ Leader Enhances Translation of the Ciliopathy Gene Inpp5e and Resistance to Oncolytic Virus Infection

    17/12/2019

    Oncolytic virus infection decouples transcription and translation in cancer cells

  5. Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity

    01/12/2019

    We determined that patient-derived leukemias transplanted into GSS zebrafish exhibit broader clonal representation compared to transplants into control hosts. GSS zebrafish incorporating error-corrected RNA sequencing establish a new standard for zebrafish xenotransplantation that more accurately recapitulates the human context, providing a more representative cost-effective preclinical model system for evaluating personalized response-based treatment in leukemia and therapies to expand human hematopoietic stem and progenitor cells in the transplant setting.

  6. Survival of Infants ≤24 Months of Age With Brain Tumors: A Population-Based Study Using the SEER Database

    04/09/2019

    While overall survival for infants with brain tumors has improved from the 1970s onwards, not every tumor type has seen a statistically significant change.

  7. The Transcription Factor SP3 Drives TNF-α Expression in Response to Smac Mimetics

    01/01/2019

    The controlled production and downstream signaling of the inflammatory cytokine tumor necrosis factor-α (TNF-α) are important for immunity and its anticancer effects.

  8. Pannexin 1 inhibits rhabdomyosarcoma progression through a mechanism independent of its canonical channel function

    02/11/2018

    The comparison of PANX1 direct interactors in RMS cells to that of skeletal muscle myoblasts may also enable a better understanding of the mechanisms activating and inhibiting PANX1 channels in physiologic and pathologic processes.

  9. Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

    23/08/2018

  10. Battling for Ribosomes: Translational Control at the Forefront of the Antiviral Response

    06/07/2018

    Viruses battle for control over the cellular protein synthesis machinery

  11. Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six‐Year Prospective Cohort Study

    01/05/2018

    These results suggest the need for trials addressing interventions in the first 2 years of chemotherapy, targeting older children and children with more severe vertebral collapse, because these children are at greatest risk for incident VF and subsequent residual vertebral deformity.

  12. Predictors of specialized pediatric palliative care involvement and impact on patterns of end-of-life care in children with cancer

    10/03/2018

    When available, SPPC, but not general palliative care, is associated with lower intensity care at the end of life for children with cancer. However, access remains uneven. These results provide the strongest evidence to date supporting the creation of SPPC teams.

  13. Smac Mimetics Synergize With Immune Checkpoint Inhibitors to Promote Tumour Immunity Against Glioblastoma

    01/02/2017

    Overall, this combinatorial approach could be highly effective in clinical application as it allows for cooperative and complimentary mechanisms in the immune cell-mediated death of cancer cells.

  14. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation

    04/08/2016

    We reviewed 22 pediatric patients with advanced myelodysplastic syndrome from a single center, diagnosed between January 2000 and December 2015. Of those, eight patients received off-label azacitidine before hematopoietic stem cell transplantation.

  15. Immunohistochemistry (IHC) Predicts High Risk Cytogenetics in Acute Myeloid Leukemia (AML)

    14/01/2015

    p53 Immunohistochemistry staining was performed on bone marrow clot and biopsy sections from AML patients diagnosed from January 2007-January 2009 and with successful cytogenetic analysis done by standard methods. 

  16. Pannexin 1 and Pannexin 3 Channels Regulate Skeletal Muscle Myoblast Proliferation and Differentiation

    01/09/2014

    Collectively, our results reveal that both Panx1 and Panx3 are expressed in skeletal muscle myoblasts and that their levels are differentially modulated during the differentiation process regulating either myoblast proliferation and/or differentiation status.

  17. Smac Mimetics and Innate Immune Stimuli Synergize to Promote Tumor Death

    15/02/2014

    As these and other adjuvants have been proven safe in clinical trials, it may be worthwhile to explore their clinical efficacy in combination with SMCs.

Researchers

  1. Tommy Michel Alain

    Scientist, CHEO Research Institute

    View Profile Email
  2. Ali Amid

    Investigator, CHEO Research Institute

    View Profile Email
  3. Rebecca Balasa

    Investigator, CHEO Research Institute

    View Profile Email
  4. Jason Berman

    CEO and Scientific Director of the CHEO Research Institute and the Vice President Research at CHEO

    View Profile Email
  5. Shawn Beug

    Scientist, CHEO Research Institute

    View Profile Email
  6. Kyle Cowan

    Scientist, CHEO Research Institute

    View Profile Email
  7. Robert Klaassen

    Investigator, CHEO Research Institute

    View Profile Email
  8. Robert Korneluk

    Senior Scientist, CHEO Research Institute

    View Profile Email
  9. Mira F Liebman

    Investigator, CHEO Research Institute

    View Profile Email
  10. Grace Maio

    Investigator, CHEO Research Institute

    View Profile Email
  11. Ewurabena Simpson

    Investigator, CHEO Research Institute

    View Profile Email
  12. Albert Tu

    Investigator, CHEO Research Institute

    View Profile Email
  13. Christina Vadeboncoeur

    Investigator, CHEO Research Institute

    View Profile Email
  14. Leanne Ward

    Senior Scientist, CHEO Research Institute

    View Profile Email

Family Leaders

  1. Bleadon Anderson

    View Profile
  2. Ellen Song

    View Profile
  3. Emilie Hageltorn

    View Profile
  4. Emilio Alarcon

    View Profile
  5. Iryna Coulter

    View Profile
  6. Kieran Peacock

    View Profile
  7. Laurie Woodward

    View Profile
  8. Linda Lefebvre

    View Profile
  9. Lisa Ricciuti

    View Profile
  10. Madleen Zapata-Martinez

    View Profile
  11. Mairead Green

    View Profile
  12. Mariann Michael

    View Profile
  13. Natasha Baechler

    View Profile
  14. Samantha Bellefeuille

    View Profile